Meaning
Quantitative analytical procedures designed to measure the biological activity of a substance on living cells or tissues are called bioassays. Such evaluations determine polymer cytotoxicity and extractable toxicity in medical-grade polyolefins, establishing whether leachable compounds inhibit cell growth during in vitro testing. Regulations govern these methods to ensure medical devices manufactured from thermoplastic resins do not transfer harmful chemical entities into biological fluids.
Resin Cytotoxicity
Material specifications dictate that compounded polymers pass standardized cell viability checks before injection molding into finished components. Virgin raw material lots undergo testing against established biological benchmarks, whereas regrind streams introduce variability that frequently triggers failure in the same protocols. Thermal degradation during barrel residence time alters molecular weight distribution, generating toxic degradation products that lower cell survival rates below regulatory thresholds.
Molding Control
Injection molding parameters directly influence biological test outcomes through thermal history management and shear rate regulation during plastication. Excessive melt temperature breaks down stabilizers, increasing leachable fractions that subsequently register positive cytotoxicity reactions in laboratory cultures. Process technicians maintain strict limits on barrel residence times and clamp pressures to preserve the chemical integrity established in the raw material datasheet.
Defect Cost
Part rejections resulting from failed biological evaluations generate substantial financial losses and halt production lines immediately upon detection. Component validation requires passing these toxicological hurdles before mass manufacturing commences, avoiding costly tool modifications and regulatory penalties. Scrap rates climb when unstable polymer sourcing introduces unknown additives that compromise cell compatibility without altering physical dimensions.